Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Dec 17, 2024

Accession no.
0001447362-24-000202
Filed
Dec 17, 2024
Trade date
Dec 13-16, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 15 non-derivative transactions. Open-market sales total $750.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 13, 2024Common StockSSaleDisposed−10,164$28.47F2−$289,369.08108,506Direct
Dec 13, 2024Common StockSSaleDisposed−381$28.47F2−$10,847.0773,225Indirect
Dec 13, 2024Common StockSSaleDisposed−357$28.47F2−$10,163.7962,586Indirect
Dec 13, 2024Common StockSSaleDisposed−113$28.47F2−$3,217.115,747Indirect
Dec 13, 2024Common StockSSaleDisposed−113$28.47F2−$3,217.115,739Indirect
Dec 13, 2024Common StockSSaleDisposed−113$28.47F2−$3,217.115,739Indirect
Dec 13, 2024Common StockSSaleDisposed−113$28.47F2−$3,217.115,739Indirect
Dec 13, 2024Common StockSSaleDisposed−3,321$29.16F9−$96,840.36105,185Direct
Dec 13, 2024Common StockSSaleDisposed−124$29.16F9−$3,615.8473,101Indirect
Dec 13, 2024Common StockSSaleDisposed−117$29.16F9−$3,411.7262,469Indirect
Dec 13, 2024Common StockSSaleDisposed−37$29.16F9−$1,078.925,710Indirect
Dec 13, 2024Common StockSSaleDisposed−37$29.16F9−$1,078.925,702Indirect
Dec 13, 2024Common StockSSaleDisposed−37$29.16F9−$1,078.925,702Indirect
Dec 13, 2024Common StockSSaleDisposed−37$29.16F9−$1,078.925,702Indirect
Dec 16, 2024Common StockSSaleDisposed−11,059$28.83F10−$318,830.9794,126Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $27.99 to $28.98, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

F9

This transaction was executed in multiple trades at prices ranging from $28.99 to $29.34, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

F10

This transaction was executed in multiple trades at prices ranging from $28.580 to $29.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)